Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2017 | Determining the optimal use of targeted therapies in mantle cell lymphoma

Michael Williams • 10 Sep 2017
iwNHL 2017
Mantle Cell Lymphoma

With the rise of novel targeted therapies, it has become increasingly important to optimize treatment sequence and treatment combinations. Michael Williams, MD and his group at the Emily Couric Clinical Cancer Center, Charlottesville, VA have been focusing on developing an optimal strategy to use novel targeted therapies such as Bruton’s tyrosine kinase (BTK) inhibitors and Bcl-2 inhibitors, among others, as front-line therapy (either in combination or as chemotherapy replacements). Here, he discusses some of the challenges his team has faced.
Recorded at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC.

More from Michael Williams

4:15
Combination studies with venetoclax (ABT-199), BCL-2 inhibitor, for non-Hodgkin lymphoma
Michael Williams • 12 Nov 2015
16:37
Panel discussion on new technologies in lymphoma - the applications of circulating tumor DNA
Ash Alizadeh et al. • 23 Sep 2016

Related Videos

3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
2:40
The impact of CAR-T on the role of SCT in lymphoma
Anna Sureda • 7 Mar 2024
0:44
A case report of CAR-T-related neurotoxicity presenting as delayed aseptic meningitis in MCL
Stefania Bramanti • 17 Feb 2024
The content of VJHemOnc is intended for healthcare professionals